Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.58 |
| ▸ | RAB9A | P51151 | 3/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.58 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | NAMPT | P43490 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16192927 | 0.93 | NPC1 (0.52) | NPC1RAB9AL3MBTL1MEN1KMT2A | |
| SCHEMBL3180689 | 0.90 | L3MBTL1 (0.61) | L3MBTL1MAPTGAANAMPTHDAC1 | |
| SCHEMBL3413772 | 0.90 | NPC1 (0.55) | NPC1RAB9AL3MBTL1MEN1KMT2A | |
| SCHEMBL11957489 | 0.87 | L3MBTL1 (0.53) | NPC1RAB9AL3MBTL1MEN1KMT2A | |
| SCHEMBL21066545 | 0.87 | KMT2A (0.52) | NPC1RAB9AL3MBTL1MEN1KMT2A | |
| SCHEMBL28230906 | 0.86 | ALDH1A1 (0.63) | NPC1RAB9AL3MBTL1MEN1KMT2A | |
| SCHEMBL24011214 | 0.85 | CASR (0.53) | NPC1RAB9AL3MBTL1MEN1KMT2A | |
| SCHEMBL2721206 | 0.84 | ALDH1A1 (0.65) | NPC1RAB9AL3MBTL1MEN1KMT2A | |
| SCHEMBL7551243 | 0.84 | L3MBTL1 (0.51) | NPC1RAB9AL3MBTL1MEN1KMT2A | |
| SCHEMBL482239 | 0.84 | L3MBTL1 (0.51) | NPC1RAB9AL3MBTL1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114957219-B | Degradation agent for targeted degradation of Gli1 protein, preparation method and application thereof | 苏州大学 | 2023-12-15 | — | — | CN | claimed |
| CN-114957219-A | Degradation agent for targeted degradation of Gli1 protein and preparation method and application thereof | 苏州大学 | 2022-08-30 | — | — | CN | claimed |
| JP-2002500641-A | — | — | 2002-01-08 | — | — | JP | claimed |
| EP-0998451-A1 | SUBSTITUTED 3,3-DIAMINO-2-PROPENENITRILES, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2000-05-10 | — | — | EP | claimed |
| WO-1998050344-A1 | SUBSTITUTED 3,3-DIAMINO-2-PROPENENITRILES, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1998-11-12 | — | — | WO | claimed |
| US-20250391519-A1 | CHEMICAL SYNTHESIS PLATFORM | UNIV GLASGOW COURT (GB) | 2025-12-25 | — | — | US | disclosed |
| CN-119968369-A | Cytotoxic imidazo [1,2-a ] pyridine compounds and their use in therapy | 迈里克斯制药有限公司 | 2025-05-09 | — | — | CN | disclosed |
| EP-4548355-A1 | CHEMICAL SYNTHESIS PLATFORM | The University Court Of The University Of Glasgow (GB) | 2025-05-07 | — | — | EP | disclosed |
| CN-118401516-A | TYK2 inhibitors, compositions and methods thereof | 凌科药业(杭州)有限公司 | 2024-07-26 | — | — | CN | disclosed |
| CN-118344346-A | Heterocyclic compounds and their use | 武田药品工业株式会社 | 2024-07-16 | — | — | CN | disclosed |
| CN-118290408-A | Heterocyclic compounds and their use | 武田药品工业株式会社 | 2024-07-05 | — | — | CN | disclosed |
| CN-118271297-A | Heterocyclic compounds and their use | 武田药品工业株式会社 | 2024-07-02 | — | — | CN | disclosed |
| US-9439890-B2 | Triazolone compounds as mPGES-1 inhibitors | GLENMARK PHARMACEUTICALS S.A. (CH) | 2016-09-13 | — | — | US | disclosed |
| CN-105408335-A | Pyrazolopyrrolidine derivatives and their use in the treatment of disease | NOVARTIS AG | 2016-03-16 | — | — | CN | disclosed |
| US-20150283117-A1 | TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS | Ichnos Sciences SA (CH) | 2015-10-08 | — | — | US | disclosed |
| US-9096545-B2 | Triazolone compounds as mPGES-1 inhibitors | GLENMARK PHARMACEUTICALS S.A. (CH) | 2015-08-04 | — | — | US | disclosed |
| US-20150087646-A1 | TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2015-03-26 | — | — | US | disclosed |
| US-7981874-B2 | Phosphorus derivatives as histone deacetylase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2011-07-19 | — | — | US | disclosed |
| US-20110059940-A1 | 2-Aryl Glycinamide Derivatives | BRISTOL- MYERS SQUIBB COMPANY | 2011-03-10 | — | — | US | disclosed |
| US-20090270351-A1 | PHOSPHORUS DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150283117-A1 | TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS | PTGES, PTGIS, PTGS1 | NPC1 1058/4885RAB9A 1553/4885L3MBTL1 4576/4885 |
| US-20150087646-A1 | TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS | PTGES, PTGS1, PTGIS | NPC1 1186/4885RAB9A 2963/4885L3MBTL1 4389/4885 |
| US-20110059940-A1 | 2-Aryl Glycinamide Derivatives | IAPP, APP, BACE1 | NPC1 254/4885RAB9A 908/4885L3MBTL1 4639/4885 |
| US-20250391519-A1 | CHEMICAL SYNTHESIS PLATFORM | SET, CBS, COASY | NPC1 849/4885RAB9A 3727/4885L3MBTL1 3322/4885 |
| US-20090270351-A1 | PHOSPHORUS DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | HDAC5, PPM1A, PTEN | NPC1 3735/4885RAB9A 4443/4885L3MBTL1 2929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.